

John A Heit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5033356/publications.pdf>

Version: 2024-02-01

98
papers

15,375
citations

87888

38
h-index

62596

80
g-index

99
all docs

99
docs citations

99
times ranked

13022
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 1998, 158, 585.	3.8	2,288
2	Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2000, 160, 809.	3.8	1,916
3	Prevention of VTE in Nonorthopedic Surgical Patients. Chest, 2012, 141, e227S-e277S.	0.8	1,819
4	Trends in the Incidence of Venous Thromboembolism during Pregnancy or Postpartum: A 30-Year Population-Based Study. Annals of Internal Medicine, 2005, 143, 697.	3.9	1,102
5	Relative Impact of Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2002, 162, 1245.	3.8	970
6	Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2000, 160, 761.	3.8	937
7	Epidemiology of venous thromboembolism. Nature Reviews Cardiology, 2015, 12, 464-474.	13.7	783
8	The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 3-14.	2.1	749
9	The Epidemiology of Venous Thromboembolism in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 370-372.	2.4	636
10	Predictors of Survival After Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 1999, 159, 445.	3.8	566
11	The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and Management. Journal of Thrombosis and Thrombolysis, 2006, 21, 23-29.	2.1	313
12	Incidence of Venous Thromboembolism in Hospitalized Patients vs Community Residents. Mayo Clinic Proceedings, 2001, 76, 1102-1110.	3.0	308
13	Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US.. Blood, 2005, 106, 910-910.	1.4	224
14	Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood, 2014, 123, 3972-3978.	1.4	167
15	American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. Genetics in Medicine, 2001, 3, 139-148.	2.4	166
16	Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood, 2019, 134, 1645-1657.	1.4	162
17	Venous Thromboembolism Epidemiology: Implications for Prevention and Management. Seminars in Thrombosis and Hemostasis, 2002, 28, 003-014.	2.7	161
18	Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement. Annals of Internal Medicine, 2000, 132, 853.	3.9	115

#	ARTICLE	IF	CITATIONS
19	Coronary Embolus. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 172-180.	2.9	113
20	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. <i>Nature Communications</i> , 2014, 5, 5303.	12.8	109
21	Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1399-1405.	2.4	101
22	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	6.2	101
23	A Genome-wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. <i>Genetic Epidemiology</i> , 2013, 37, 512-521.	1.3	99
24	Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study. <i>Thrombosis and Haemostasis</i> , 1997, 77, 032-038.	3.4	96
25	Thrombophilia: Common Questions on Laboratory Assessment and Management. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 127-135.	2.5	94
26	Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. <i>Blood</i> , 2017, 130, 109-114.	1.4	90
27	Reasons for the persistent incidence of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017, 117, 390-400.	3.4	89
28	Perioperative management of the chronically anticoagulated patient. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 81-87.	2.1	87
29	Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. <i>Thrombosis Research</i> , 2010, 126, 373-378.	1.7	83
30	Predicting the risk of venous thromboembolism recurrence. <i>American Journal of Hematology</i> , 2012, 87, S63-7.	4.1	82
31	Risk factors for venous thromboembolism. <i>Clinics in Chest Medicine</i> , 2003, 24, 1-12.	2.1	77
32	Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. <i>Blood</i> , 2011, 118, 4992-4999.	1.4	67
33	Risk of site-specific cancer in incident venous thromboembolism: A population-based study. <i>Thrombosis Research</i> , 2015, 135, 472-478.	1.7	61
34	Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study. <i>Thrombosis Research</i> , 2016, 139, 29-37.	1.7	58
35	The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. <i>Blood</i> , 2012, 119, 2392-2400.	1.4	56
36	Determinants of Plasma Fibrin D-Dimer Sensitivity for Acute Pulmonary Embolism as Defined by Pulmonary Angiography. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 235-240.	2.5	42

#	ARTICLE	IF	CITATIONS
37	Identifying In-Hospital Venous Thromboembolism (VTE). <i>Medical Care</i> , 2008, 46, 127-132.	2.4	41
38	Predictors of Venous Thromboembolism Recurrence, Adjusted for Treatments and Interim Exposures: A Population-based Case-cohort Study. <i>Thrombosis Research</i> , 2015, 136, 298-307.	1.7	40
39	Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. <i>American Journal of Medicine</i> , 2018, 131, 307-316.e2.	1.5	40
40	Identification of unique venous thromboembolism-susceptibility variants in African-Americans. <i>Thrombosis and Haemostasis</i> , 2017, 117, 758-768.	3.4	35
41	Direct Medical Costs Attributable to Cancer-Associated Venous Thromboembolism: A Population-Based Longitudinal Study. <i>American Journal of Medicine</i> , 2016, 129, 1000.e15-1000.e25.	1.5	28
42	Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles. <i>Platelets</i> , 2016, 27, 32-42.	2.3	27
43	Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: A population-based longitudinal study. <i>Surgery</i> , 2015, 157, 423-431.	1.9	26
44	Prevalence and risk factors for post thrombotic syndrome after deep vein thrombosis in children: A cohort study. <i>Thrombosis Research</i> , 2015, 135, 347-351.	1.7	25
45	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. <i>Physiological Genomics</i> , 2016, 48, 33-41.	2.3	23
46	The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. <i>Chest</i> , 2003, 124, 40S-48S.	0.8	21
47	Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism: A 35-Year Population-Based Study. <i>Blood</i> , 2006, 108, 1488-1488.	1.4	18
48	Sensitivity and Specificity of Denaturing High-Pressure Liquid Chromatography for Unknown Protein C Gene Mutations. <i>Genetic Testing and Molecular Biomarkers</i> , 2001, 5, 39-44.	1.7	16
49	Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study. <i>Thrombosis Research</i> , 2015, 135, 1110-1116.	1.7	16
50	Are myocardial infarction and venous thromboembolism associated? Population-based case-control and cohort studies. <i>Thrombosis Research</i> , 2014, 134, 593-598.	1.7	14
51	Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1331-1349.	3.8	12
52	Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COVID.S COVID-19 Vaccination. <i>JAMA Internal Medicine</i> , 2022, 182, 80.	5.1	11
53	Germline mutations in Peruvian patients with hemophilia B: Pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern. <i>Human Mutation</i> , 1998, 11, 372-376.	2.5	10
54	Rethinking Guidelines for VTE Risk Among Nursing Home Residents. <i>Chest</i> , 2014, 146, 412-421.	0.8	9

#	ARTICLE	IF	CITATIONS
55	Estimated Annual Number of US Acute-Care Hospital Inpatients Meeting ACCP Criteria for Venous Thromboembolism (VTE) Prophylaxis.. Blood, 2005, 106, 903-903.	1.4	8
56	Identification of Patients At High Risk for Recurrent Venous Thromboembolism by Whole Blood Gene Expression Analysis. Blood, 2011, 118, 2305-2305.	1.4	8
57	Venous stasis syndrome: the long-term burden of deep vein thrombosis. British Journal of Hospital Medicine, 2003, 64, 593-598.	0.2	6
58	Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes. Thrombosis and Haemostasis, 2018, 118, 1316-1328.	3.4	6
59	Novel Risk Factors for Venous Thromboembolism (VTE): A Population-Based Case-Control Study.. Blood, 2005, 106, 1618-1618.	1.4	5
60	Venous Gangrene and Intravascular Coagulation and Fibrinolysis in a Patient Treated with Rivaroxaban. American Journal of Medicine, 2014, 127, e7-e8.	1.5	4
61	Periprocedural Anticoagulation Management of Patients with Thrombophilia. American Journal of Medicine, 2016, 129, 986-992.	1.5	4
62	The Risk of Venous Thromboembolism (VTE) among Cancer Patients by Tumor Site: A Population-Based Study.. Blood, 2004, 104, 2596-2596.	1.4	4
63	Frequency of Heparin-Induced Thrombocytopenia and Heparin-Dependent IgG Antibodies in Hematopoietic Stem Cell Transplant Recipients.. Blood, 2006, 108, 4059-4059.	1.4	4
64	Current Management of Acute Symptomatic Deep Vein Thrombosis. American Journal of Cardiovascular Drugs, 2001, 1, 45-50.	2.2	3
65	Mapping Out the Future in Venous Thromboembolism and Acute Coronary Syndromes. Seminars in Thrombosis and Hemostasis, 2002, 28, 033-040.	2.7	3
66	The association of copy number variation and percent mammographic density. BMC Research Notes, 2015, 8, 297.	1.4	2
67	Atherosclerosis as a Risk Factor for Venous Thromboembolism (VTE): A Population-Based Cohort Study.. Blood, 2004, 104, 2584-2584.	1.4	2
68	Role of Venous Outflow Obstruction and Venous Valvular Incompetence as Mechanisms for Venous Stasis Syndrome Following Deep Vein Thrombosis: A Population-Based Cohort Study.. Blood, 2006, 108, 1495-1495.	1.4	2
69	The Effect of Patient Age and Calendar Year on the Incidence of Idiopathic vs. Secondary Venous Thromboembolism (VTE): A Population-Based Cohort Study.. Blood, 2004, 104, 3516-3516.	1.4	2
70	Venous Thromboembolism (VTE) Risk Factors among Nursing Home Residents: A Population-Based Case-Control Study.. Blood, 2004, 104, 2608-2608.	1.4	2
71	Intensity of Warfarin Anticoagulation as an Independent Predictor of 6-Month Recurrence after Deep Vein Thrombosis or Pulmonary Embolism: A Population-Based Cohort Study.. Blood, 2006, 108, 718-718.	1.4	2
72	Comparison of characteristics from White- and Black-Americans with venous thromboembolism: A cross sectional study. American Journal of Hematology, 2010, 85, 908-908.	4.1	1

#	ARTICLE	IF	CITATIONS
73	Identification of Genetic Interaction with Risk Factors Using a Time-To-Event Model. International Journal of Environmental Research and Public Health, 2017, 14, 1228.	2.6	1
74	Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience.. Blood, 2007, 110, 3965-3965.	1.4	1
75	Venous Thromboembolism (VTE) Characteristics among White- and Black-Americans: a Cross Sectional Study. Blood, 2008, 112, 3831-3831.	1.4	1
76	Association of Gene-Gene Interactions with Venous Thromboembolism (VTE): A Pathway-Directed Candidate-Gene Case-Control Study.. Blood, 2009, 114, 150-150.	1.4	1
77	Association of Gene-Environment Interactions with Venous Thromboembolism (VTE): A Merged/Imputed Genome-Wide Scan/Candidate-Gene Case-Control Study. Blood, 2011, 118, 2295-2295.	1.4	1
78	The Seasonal Incidence of Venous Thromboembolism (VTE): A Population-Based Cohort Study.. Blood, 2004, 104, 3503-3503.	1.4	1
79	Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study. Blood, 2008, 112, 3822-3822.	1.4	1
80	Risk Factors for Venous Thromboembolism (VTE) Among Nursing Home Residents: A Population-Based Case Control Study. Blood, 2010, 116, 476-476.	1.4	1
81	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	3.3	0
82	Tumor Site and Metastases as Predictors of Venous Thromboembolism Recurrence among Active Cancer Patients with Incident Deep Vein Thrombosis or Pulmonary Embolism: A Population-Based Cohort Study.. Blood, 2006, 108, 4096-4096.	1.4	0
83	Intensity of Heparin Anticoagulation as an Independent Predictor of 14-Day Recurrence after Deep Vein Thrombosis or Pulmonary Embolism: A Population-Based Cohort Study.. Blood, 2006, 108, 873-873.	1.4	0
84	Risk Factors for Venous Thromboembolism (VTE) among Patients with Active Hematological Cancer: A Population-Based Case-Control Study.. Blood, 2007, 110, 1642-1642.	1.4	0
85	Platelet function and relationship to coronary artery disease (CAD) risk in early menopausal women. FASEB Journal, 2010, 24, 589.5.	0.5	0
86	Are Beta-Receptor and Angiotensin-Blocking Drugs Protective Against Venous Thromboembolism (VTE)? A Population Based Case-Control Study. Blood, 2010, 116, 5118-5118.	1.4	0
87	Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients. Blood, 2010, 116, 4219-4219.	1.4	0
88	Association of Gene-Environment Interactions with Venous Thromboembolism (VTE): A Pathway-Directed Candidate-Gene Case-Control Study. Blood, 2010, 116, 480-480.	1.4	0
89	HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery. Blood, 2011, 118, 1159-1159.	1.4	0
90	Impact of Interim Hospitalizations on Risk of Venous Thromboembolism (VTE) Recurrence: A Nested Case-Cohort Study. Blood, 2011, 118, 1241-1241.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Association of Gene-Gene Interactions with Venous Thromboembolism (VTE): A Merged/Imputed Genome-Wide Scan/Candidate-Gene Case-Control Study. <i>Blood</i> , 2011, 118, 1242-1242.	1.4	0
92	Detection of Continuous Flow Left Ventricular Assist Device -Associated Acquired Von Willebrand Factor (VWF) Abnormality by An Automated Immunoturbidimetric VWF Activity Assay. <i>Blood</i> , 2011, 118, 2273-2273.	1.4	0
93	Identification of Venous Thromboembolism (VTE)-Associated Novel Variants in the ABO Gene Using Targeted Deep Sequencing. <i>Blood</i> , 2011, 118, 709-709.	1.4	0
94	Replication of Candidate Gene Single Nucleotide Polymorphisms (SNPs) Previously Reported As Associated with Venous Thromboembolism (VTE). <i>Blood</i> , 2011, 118, 1238-1238.	1.4	0
95	Trends in the Incidence of Venous Thromboembolism Adjusted for Body Mass Index (BMI).. <i>Blood</i> , 2012, 120, 2256-2256.	1.4	0
96	Single Nucleotide Polymorphisms (SNPs) Associated with Pulmonary Embolism (PE): A Genome-Wide Association Study (GWAS). <i>Blood</i> , 2012, 120, 1148-1148.	1.4	0
97	Thrombophilia Effect On Periprocedural Thromboembolism and Bleeding in Chronically Anticoagulated Patients. <i>Blood</i> , 2012, 120, 3404-3404.	1.4	0
98	Abstract 303: Risk Factors for Venous Thromboembolism (VTE) among Patients with Neurologic Disease and Leg Paresis: A Population-based Case-control Study.. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	2.4	0